1. BSCR (2007). Autumn Meeting, http://www.bscr.org/autumn_2007_meeting.html [accessed 22 Apr 2008].
2. The anaesthetized methoxamine-sensitized rabbit model of torsades de pointes;Carlsson;Pharmacol Ther,2008
3. Proarrhythmic effects of the class I11 agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations;Carlsson;Cardiovasc Res,1993
4. A drug for men and women — how important is gender as a TDP disposition risk factor?;Coker;Pharmacol Ther,2008
5. Committee for Medicinal Products for Human Use (2005). ICH Note for Guidance on The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (ICH S7B) (CHMP/ICH/423/02) EMEA, London, 25 May 2005. http://www.emea.eu.int/pdfs/human/ich/042302en.pdf